Genetic variations in CYP2A6 predict efficacy of neoadjuvant letrozole concurrent with chemotherapy in locally advanced hormone receptor-positive breast cancer.

ABSTRACT:

Purpose

We conducted a retrospective exploratory analysis of prospective cohort to investigate the impact of CYP2A6 metabolizer status on predicting the efficacy and prognosis of neoadjuvant chemotherapy combined with letrozole.

Method

Three allelic variants that related to the abolished or reduced activity of CYP2A6 enzyme and 7 other single nucleotide polymorphisms (SNPs) in the CYP2A6 locus were examined from whole blood samples before neoadjuvant treatment, and patients were classified into 3 metabolizer status subgroups ('normal', 'intermediate' and 'slow' metabolizers) according to CYP2A6 genotypes.

Result

Our study included 56 patients received neoadjuvant chemotherapy combined with letrozole. The pCR rate in the CYP2A6 intermediate/slow metabolizers (29.2%) wa

SUBMITTER: Wu Y 

PROVIDER: S-EPMC12444925 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature